Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04824092 · ClinicalTrials.gov registry record · Phase 3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
A Phase 3 study of Diffuse Large B Cell Lymphoma, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 899
- Enrollment target
- 20
- Study locations
NCT04824092 is a Phase 3 study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 899 participants, above the 211-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (326% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT04824092, a Phase 3 study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 899 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Tafasitamab
Study Locations (20)
California
- MorphoSys Research Site - Anaheim
- MorphoSys Research Site - Clovis
- MorphoSys Research Site - Fullerton
- MorphoSys Research Site - Harbor City
- MorphoSys Research Site - Los Angeles
- MorphoSys Research Site - San Diego
- MorphoSys Research Site - Whittier
Maryland
- MorphoSys Research Site - Baltimore
- MorphoSys Research Site - Bethesda
- MorphoSys Research Site - Columbia
Kentucky
- MorphoSys Research Site - Lexington
- MorphoSys Research Site - Louisville
Minnesota
- MorphoSys Research Site - Minneapolis
- MorphoSys Research Site - Rochester
Alabama
- MorphoSys Research Site - Daphne
Colorado
- MorphoSys Research Site - Aurora
Florida
- MorphoSys Research Site - Jacksonville
Hawaii
- MorphoSys Research Site - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 899 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04824092
The ClinicalTrials.gov registry entry for NCT04824092 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 899 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 211-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (326% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04824092 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Maryland, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04824092 about?
NCT04824092 is a clinical study titled "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients". This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ve...
What is the current status of trial NCT04824092?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 899 participants. The study started on 2021-05-11. Estimated completion is 2027-11-01.
What conditions does trial NCT04824092 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT04824092?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Lenalidomide (DRUG), Tafasitamab (DRUG).
Who is sponsoring clinical trial NCT04824092?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04824092 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RECRUITING · Phase 3
-
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RECRUITING · Phase 3
-
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.